Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method including a person visual behaviour parameter providing, during which a person visual behaviour parameter indicative of the visual behaviour of the person relative to a given state of the environment is provided; a reference value providing, during which a first value of the person visual behaviour parameter corresponding to a reference state of the environment is provided; a visual and/or proprioceptive modification providing, during which a visual and/or proprioceptive modification of the reference state of the environment is provided so as to define a modified state of the environment; and determining, during which an optical parameter of the optical system is determined based on the first value of the person visual behaviour parameter and on a second value of the person visual behaviour parameter associated with t

Abstract: It is provided a method of expanding dendritic (DC) cells and/or natural killer (NK) cells in vivo in a patient comprising the steps of producing a graft of stem and progenitor cells cultured with UM171 or analogues therefrom and expanded before being administered to the patient. The expansion or increase in dendritic (DC) cells and/or natural killer (NK) cells population in the patient results in an increase immune response reducing transplant related mortality (TRM), severe graft-versus-host disease (GVHD), relapse, and/or severe viral infections.

Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.

Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.

Abstract: Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as AML is also described.

Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.

Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.

Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.

Abstract: The present disclosure provides methods of treating cancer by silencing tumor-innervating sensory neurons. The methods include treating cancer by genetic ablation of ion channels (e.g., TRPV1 or NaV1.8), local pharmacological silencing or blockade of neuropeptide release from tumor-innervating nociceptor (e.g., with QX-314 and BoNT/a), as well as the antagonism of the CGRP receptor RAMP1 (e.g., with BIBN 4096).

Abstract: Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.

Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method including a person visual behaviour parameter providing, during which a person visual behaviour parameter indicative of the visual behaviour of the person relative to a given state of the environment is provided; a reference value providing, during which a first value of the person visual behaviour parameter corresponding to a reference state of the environment is provided; a visual and/or proprioceptive modification providing, during which a visual and/or proprioceptive modification of the reference state of the environment is provided so as to define a modified state of the environment; and determining, during which an optical parameter of the optical system is determined based on the first value of the person visual behaviour parameter and on a second value of the person visual behaviour parameter associated with t

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method.

Abstract: There is described a medical device for management of the axial length growth of an eye of a subject. The device comprises a central region having a first power, a transition region surrounding the central region, and a peripheral region surrounding the transition region and having a second power. The transition region has a width at most equal to 1.5 mm. The second power is chosen based on the first power to achieve a target net power, the target net power being the addition of the first power and the second power. The surface area of the central and peripheral regions is chosen as a function of the surface area of the pupil of the eye. Furthermore, the curve of power within the transition region is steep between the first power and the second power so that the transition region generates no optically usable power.

Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

Abstract: A system simulating a decisional process in a mammal brain about characteristics of motions related to body gestures of a visually observed body through a simulated visual path is provided. The system includes an interface toward simulated neuronal structures, the interface at least converting luminous information of the observed body to an optic flow data stream conveying information related to the visually observed body and that can be processed in the simulated neuronal structures, the system being a feed-forward system and comprising hierarchically from the visual observation to the decision: the simulated visual path and its interface, a simulated local motion direction detection neuronal structure for the detection of motion directions with receptive fields, a simulated opponent motions detection neuronal structure, a simulated complex patterns detection neuronal structure, and a simulated motion pattern detection neuronal structure.

Abstract: A method for modulating a movement of a body part comprising: acquiring movement event data relating to the body part during a movement event, the movement event data including: a movement event parameter requiring modulation, a trigger value representative of a first time point in the movement event, and a target value representative of desired movement at a second, later, time point in the movement event; acquiring in real-time current movement data associated with a current movement event of the body part, the current movement data including current values of the movement event parameter; analyzing the current movement data to determine presence of the trigger value in the current movement event; and in response to identification of the trigger value in the current movement data, causing a brain stimulation assembly to apply a predetermined modulation signal to a brain motor region of the subject to cause the modulation of the body part towards the target value at the second time point in the current movem